Deals channel feed

Fore­site re­turns to the SPAC well, as in­vestors won­der how long the run can last

5 years ago

Once laser-fo­cused on liv­er, Mi­NA takes swing at neu­rol­o­gy with Servier's back­ing

5 years ago

Grit­stone con­tin­ues Covid-19 push with deal to de­vel­op 'self-am­pli­fy­ing RNA' vac­cines, as shares con­tin­ue bal­loon­ing

5 years ago
Coronavirus

Lon­za hits the ex­it on gel and liq­uid cap­sules, of­fload­ing 2 pro­duc­tion sites to NextPhar­ma

5 years ago
Manufacturing

Eli Lil­ly tees up dis­cov­ery pact worth more than $1.6B with Merus for T cell-fo­cused bis­pe­cif­ic an­ti­bod­ies

5 years ago
Discovery

Pe­ter Thiel's psy­che­delics-fo­cused ATAI ac­quires ma­jor­i­ty stake in Recog­ni­fy and its lead schiz­o­phre­nia can­di­date

5 years ago

Look­ing to build in red-hot vi­ral vec­tor space, Ther­mo Fish­er inks $878M deal for Bel­gian man­u­fac­tur­er's 2 plants

5 years ago
Manufacturing

Acor­da of­floads man­u­fac­tur­ing op­er­a­tions to Catal­ent for $70M amid lat­est re­struc­tur­ing to keep the ship afloat

5 years ago
Manufacturing

Take­da eyes path­way to nat­ur­al killer ther­a­pies, tee­ing up $100M to part­ner with KSQ for its CRISPR-screened mol­e­cules

5 years ago
Cell/Gene Tx

Am­gen ponies up $240M for Michi­gan dis­cov­ery out­fit's den­drit­ic cell tar­get­ing mol­e­cules for au­toim­mune dis­or­ders

5 years ago

On a mis­sion to 'u­ni­fy' drug dis­cov­ery and cell-line de­vel­op­ment, Ab­Sci ac­quires AI out­fit De­n­ovi­um

5 years ago
AI

Dou­bling down on on­col­o­gy, Sanofi buys in­to a new check­point in­hibitor with a $125M down pay­ment

5 years ago

Boehringer In­gel­heim en­lists a UK start­up in a mile­stone-heavy quest for 'dark anti­gen­s'

5 years ago

No­var­tis brings BeiGene's promis­ing check­point in­hibitor in­to the fold, but what about high­ly tout­ed spar­tal­izum­ab?

5 years ago

#JPM21: Resh­ma Ke­wal­ra­mani is on the hunt for 'mid-to late-stage as­sets,' new tools to re­plen­ish Ver­tex pipeline

5 years ago

Glax­o­SmithK­line backs a pre­clin­i­cal ac­ne treat­ment from Eli­go Bio­science that us­es CRISPR to kill bac­te­ria

5 years ago

EQRx scores $500M to dri­ve its dis­rup­tive drug pric­ing mod­el and late-stage on­col­o­gy hope­fuls to mar­ket

5 years ago

Sanofi CEO Paul Hud­son’s lat­est M&A gam­bit adds new eczema drug in $1.5B buy­out. And he’s steer­ing back in­to a mar­ket mael­strom

5 years ago

Chimerix places its bets on On­co­ceu­tic­s' dopamine an­tag­o­nist for rare brain can­cer in quest to sal­vage its im­age

5 years ago

Mer­ck KGaA snaps up Ger­man CD­MO in boost to mR­NA port­fo­lio — in­clud­ing for Covid-19

5 years ago
Manufacturing

Der­mi­ra vets li­cense back can­di­dates from Eli Lil­ly to launch their own up­start

5 years ago
Startups

Bris­tol My­ers Squibb ices li­cens­ing pact with Ar­se­nal­Bio to draft its de­sign­er T cells in­to the sol­id tu­mor fight

5 years ago
R&D

EX­CLU­SIVE: Zai Lab’s Saman­tha Du scoops up Chi­na rights to an au­toim­mune drug with a hefty $175M li­cens­ing deal — heav­i­ly front­ed with cash and stock

5 years ago

So why is Alex­ion pay­ing $100M for a PRV as As­traZeneca lines up their $39B buy­out?

5 years ago
Pharma
First page Previous page 81828384858687 Next page Last page
A service from the Financial Times